(Q37050248)

17 August 2017

1 reference

title

Update on the changing epidemiology of Clostridium difficile-associated disease (English)

1 reference

17 August 2017

main subject

Clostridium difficile

0 references

1 reference

Lynne V McFarland

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

Nature Reviews Gastroenterology & Hepatology

17 August 2017

published in

1 reference

17 August 2017

volume

5

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

40-48

1 reference

Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

Clostridium difficile PCR ribotypes in calves, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

Clostridium difficile-associated diarrhea in 200 Canadian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

Implications of the changing face of Clostridium difficile disease for health care practitioners

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

An epidemic, toxin gene-variant strain of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Nosocomial acquisition of Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Clostridium difficile: recent epidemiologic findings and advances in therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Revised nomenclature of Clostridium difficile toxins and associated genes

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Recommendations for surveillance of Clostridium difficile-associated disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

New definitions will help, but cultures are critical for resolving unanswered questions about Clostridium difficile

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Hypervirulent strains of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Pneumococcal vaccine--direct and indirect ("herd") effects

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Emergence of Clostridium difficile-associated disease in North America and Europe.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

First isolation of Clostridium difficile 027 in Japan

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Emergence and Control of Fluoroquinolone-Resistant, Toxin A–Negative, Toxin B–Positive Clostridium difficile

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Community-acquired Clostridium difficile diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Antibiotic-associated diarrhoea and Clostridium difficile in the community

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Prevalence of zoonotic agents in dogs visiting hospitalized people in Ontario: implications for infection control

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Pediatric Clostridium difficile: a phantom menace or clinical reality?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Evaluation of an interdisciplinary re-isolation policy for patients with previous Clostridium difficile diarrhea

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Use of hypochlorite solution to decrease rates of Clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Clostridium difficile-associated disease: new challenges from an established pathogen.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Effectiveness of environmental and infection control programs to reduce transmission of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Hospital-based strategies for combating resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1029

7 January 2021

Identifiers

DOI

10.1038/NCPGASTHEP1029

1 reference

17 August 2017

1 reference